Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was founded in 1989 and is based in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Berhyanda Limited.

Revenue projections:

Revenue projections for SUVENPHAR
Revenue projections for SUVENPHAR

With SUVENPHAR's revenues forecasted to be lower than last year's, investors are expected to be cautious. A decline in revenue typically harms the company's bottom line, reducing profitability and making investors less confident about the company's ability to sustain its financial health.

Financial Ratios:

currentRatio 0.000000
forwardPE 62.828648
debtToEquity 1.945000
earningsGrowth 0.755000
revenueGrowth 0.397000
grossMargins 0.627760
operatingMargins 0.316950
trailingEps 10.950000
forwardEps 0.000000

SUVENPHAR's forward PE is too high, potentially limiting future gains and posing a risk of a price correction. This valuation must be carefully considered with other fundamental metrics to evaluate whether the stock is worth its current price.
SUVENPHAR's positive earnings and revenue growth indicate that the company is on track to expand its business. This growth suggests a strong financial outlook, with increasing profits and sales positioning SUVENPHAR for continued success in the market.
SUVENPHAR's positive gross and operating margins reflect strong financial performance. These metrics indicate that the company is efficiently managing its operations and generating healthy profits, contributing to a solid financial position.

Price projections:

Price projections for SUVENPHAR
Price projections for SUVENPHAR

Suven Pharmaceuticals Limited's present price, in relation to projections, does not offer clear risks or opportunities. This stable scenario suggests a period of consolidation, where investors might prefer to hold off on significant changes in strategy.

Recommendation changes over time:

Recommendations trend for SUVENPHAR
Recommendations trend for SUVENPHAR


The analysts' recent buy bias for Suven Pharmaceuticals Limited indicates strong confidence in the stock's future performance. This could encourage more investors to view Suven Pharmaceuticals Limited as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.